These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 2246822

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z.
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 6. [IgA RIPA inhibitor in a case of acquired von Willebrand syndrome].
    Takai Y, Koya H, Himei S, Hayashi H.
    Rinsho Ketsueki; 1989 Dec; 30(12):2183-8. PubMed ID: 2621801
    [Abstract] [Full Text] [Related]

  • 7. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR, Williams SB, McKeown LP, Rick ME, Maisonneuve P, Jenneau C, Sultan Y.
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [Abstract] [Full Text] [Related]

  • 11. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Oct; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 12. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC, Lin JS, Lin DS, Hsu SC, Lin B.
    Thromb Res; 2003 Oct; 112(5-6):291-5. PubMed ID: 15041272
    [Abstract] [Full Text] [Related]

  • 13. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 16. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M, Kimura A, Chiba Y, Yoshida Y.
    Thromb Haemost; 1988 Jun 16; 59(3):485-90. PubMed ID: 3142084
    [Abstract] [Full Text] [Related]

  • 17. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.
    Acta Haematol; 2009 Jun 16; 121(2-3):145-53. PubMed ID: 19506361
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus.
    Viallard JF, Pellegrin JL, Vergnes C, Borel-Derlon A, Clofent-Sanchez G, Nurden AT, Leng B, Nurden P.
    Br J Haematol; 1999 May 16; 105(2):532-7. PubMed ID: 10233433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.